Clinical Trial Update: Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Remix Therapeutics is conducting a Phase 1/2 trial of REM-422 in patients with recurrent, metastatic, or unresectable adenoid cystic carcinoma. The study is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoid Cystic Carcinoma

Drugs mentioned

• REM-422

Snippet

Sponsor: Remix Therapeutics | Conditions: Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma | Phase 1, Phase 2 | Status: RECRUITING